ES2447843T3 - Polip�ptidos de Lutzomyia longipalpis y m�todos de uso - Google Patents

Polip�ptidos de Lutzomyia longipalpis y m�todos de uso Download PDF

Info

Publication number
ES2447843T3
ES2447843T3 ES09158294T ES09158294T ES2447843T3 ES 2447843 T3 ES2447843 T3 ES 2447843T3 ES 09158294 T ES09158294 T ES 09158294T ES 09158294 T ES09158294 T ES 09158294T ES 2447843 T3 ES2447843 T3 ES 2447843T3
Authority
ES
Spain
Prior art keywords
sec
polypeptide
acid sequence
longipalpis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09158294T
Other languages
English (en)
Spanish (es)
Inventor
Jesus G Valenzuela
Jose M.C. Ribeiro
Aldina Barral
Manoel Netto
Claudia Brodskyn
Regis Gomes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacao Oswaldo Cruz
GOVERNMENT OF US SECRETARY OF Department O
US Department of Health and Human Services
Original Assignee
Fundacao Oswaldo Cruz
GOVERNMENT OF US SECRETARY OF Department O
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz, GOVERNMENT OF US SECRETARY OF Department O, US Department of Health and Human Services filed Critical Fundacao Oswaldo Cruz
Application granted granted Critical
Publication of ES2447843T3 publication Critical patent/ES2447843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES09158294T 2002-10-29 2003-10-29 Polip�ptidos de Lutzomyia longipalpis y m�todos de uso Expired - Lifetime ES2447843T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42230302P 2002-10-29 2002-10-29
US422303 2002-10-29

Publications (1)

Publication Number Publication Date
ES2447843T3 true ES2447843T3 (es) 2014-03-13

Family

ID=32230337

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09158294T Expired - Lifetime ES2447843T3 (es) 2002-10-29 2003-10-29 Polip�ptidos de Lutzomyia longipalpis y m�todos de uso

Country Status (10)

Country Link
US (6) US7485306B2 (https=)
EP (2) EP1572968B1 (https=)
JP (2) JP2006516187A (https=)
AT (1) ATE429487T1 (https=)
AU (1) AU2003287267A1 (https=)
BR (1) BR0315872A (https=)
DE (1) DE60327366D1 (https=)
ES (1) ES2447843T3 (https=)
MX (1) MXPA05004714A (https=)
WO (1) WO2004039958A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545575A4 (en) 2002-09-19 2006-04-05 Us Gov Health & Human Serv P. ARIASI POLYPEPTIDE, P. PERNICIOSUS POLYPEPTIDES AND METHOD OF USE
ES2447843T3 (es) 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
WO2010021940A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insect proteins as adjuvants to accelerate the immune response
JP5590986B2 (ja) 2010-06-23 2014-09-17 株式会社シマノ 釣り用リールのワンウェイクラッチ
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
CA1340456C (en) 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
ATE138106T1 (de) 1988-07-20 1996-06-15 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5397772A (en) * 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
RO116459B1 (ro) 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
PT716697E (pt) 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
ES2168380T3 (es) 1994-07-15 2002-06-16 Organon Teknika Bv Utilizacion de arn polimerasa para mejorar un procedimiento de amplificacion de acido nucleico.
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
US7388089B2 (en) 2001-06-19 2008-06-17 The United States Of America As Represented By The Department Of Health And Human Services Anti-arthropod vector vaccines method of selecting and uses thereof
EP1545575A4 (en) 2002-09-19 2006-04-05 Us Gov Health & Human Serv P. ARIASI POLYPEPTIDE, P. PERNICIOSUS POLYPEPTIDES AND METHOD OF USE
ES2447843T3 (es) * 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso

Also Published As

Publication number Publication date
US20090117139A1 (en) 2009-05-07
US9120867B2 (en) 2015-09-01
BR0315872A (pt) 2006-07-18
ATE429487T1 (de) 2009-05-15
US10314900B2 (en) 2019-06-11
EP2085467A2 (en) 2009-08-05
US9382302B2 (en) 2016-07-05
EP1572968A2 (en) 2005-09-14
JP2010142226A (ja) 2010-07-01
EP2085467A3 (en) 2009-10-14
US8628780B2 (en) 2014-01-14
EP1572968A4 (en) 2006-07-19
WO2004039958A2 (en) 2004-05-13
AU2003287267A1 (en) 2004-05-25
US20160279211A1 (en) 2016-09-29
JP2006516187A (ja) 2006-06-29
US20150315254A1 (en) 2015-11-05
US9884100B2 (en) 2018-02-06
US20140093531A1 (en) 2014-04-03
DE60327366D1 (de) 2009-06-04
EP1572968B1 (en) 2009-04-22
US7485306B2 (en) 2009-02-03
EP2085467B1 (en) 2013-12-11
US20180147269A1 (en) 2018-05-31
US20060051364A1 (en) 2006-03-09
MXPA05004714A (es) 2006-03-17
WO2004039958A3 (en) 2005-12-08
AU2003287267A8 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
US10314900B2 (en) Lutzomyia longipalpis polypeptides and methods of use
Dias et al. Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis
US9228002B2 (en) Leishmania vaccine using sand fly salivary immunogen
ES2255553T3 (es) Antigenos de leishmania para el tratamiento y diagnositico de la leishmaniasis.
US20100196381A1 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
US20040171821A1 (en) Anti-arthropod vector vaccines method of selecting and uses thereof
BRPI9916549B1 (pt) Composição farmacêutica, proteína, polinucleotídeo
ES2395923T3 (es) Uso de histonas específicas para el tratamiento de enfermedades parasitarias
ES2273670T3 (es) Usos de polinucleotidos y polipeptidos casb618.
ES2322845T3 (es) Polipeptido anticomplemento de las glandulas salivales de la garrapata ixodes ricinus.
ES2287145T3 (es) Aislado de neospora caninum.
KR100568193B1 (ko) 전염성 에프 낭병의 예방을 위한 전염성 에프 낭병바이러스 항원결정부위를 포함한 ｄｎａ 백신
Warter et al. li zyxwvutsrqponmlkjihgfedcbaZYX
HK1150616B (en) Leishmania vaccine using sand fly salivary immunogen